Human Papillomavirus Vaccination After COVID-19

Area of Science:

• Public Health
• Vaccinology
• Global Health

Background:

• The COVID-19 pandemic has significantly disrupted routine immunization programs globally.
• This disruption poses a threat to the uptake of essential vaccines like the human papillomavirus (HPV) vaccine, particularly in low- and lower-middle income countries.
• The World Health Organization's cervical cancer elimination strategy heavily relies on HPV vaccination, screening, and treatment.

Purpose of the Study:

• To analyze the impact of the COVID-19 pandemic on HPV vaccination uptake in low- and lower-middle income countries.
• To identify current opportunities and barriers to achieving high HPV vaccination coverage.
• To propose key recommendations for successful HPV vaccination programs and cervical cancer elimination.

Main Methods:

• This study discusses the challenges and strategies related to HPV vaccination in resource-limited settings.
• It reviews the impact of global health crises on vaccine delivery systems.
• The analysis focuses on policy and implementation recommendations.

Main Results:

• COVID-19 has caused major disruptions to immunization services, delaying new vaccine introductions.
• Significant barriers exist for achieving high HPV vaccination uptake in low- and lower-middle income countries.
• The pandemic exacerbates existing challenges in delivering essential health services.

Conclusions:

• Increased global financial investment is crucial for HPV vaccination programs.
• Improving vaccine supply, adopting a single-dose schedule, and enhancing education are vital.
• Universal school-based delivery models are recommended to accelerate HPV vaccine uptake and support cervical cancer elimination efforts.